Background
==========

Colorectal cancer (CRC), is the third most common cancer in the United States, and in 2018 there were an estimated 140,250 new cases resulting in 50,630 associated deaths \[[@b1-medscimonit-25-2397]\]. CRC is the third leading cause of cancer mortality in both men and women \[[@b2-medscimonit-25-2397]\]. The incidence of CRC has been declining during the past four decades, mainly due to the reduced risk factors and the use of colonoscopic screening \[[@b2-medscimonit-25-2397]\]. In patients who have been diagnosed with CRC, the survival and prognosis have improved annually, partly due to the development of improved surgical management and improved systemic chemotherapy regimens \[[@b3-medscimonit-25-2397]\]. The survival outcome for patients with a diagnosis of CRC has been associated with clinical and histopathological factors, including the tumor site, tumor type, histologic grade, the American Joint Committee on Cancer (AJCC) stage, tumor node metastasis (TNM) status, and a comprehensive treatment strategy \[[@b4-medscimonit-25-2397]\].

Recently, clinicians have become increasingly aware of the impact of sociodemographic factors, especially the insurance status, on the diagnosis, treatment, and prognosis of patients with cancer. Previous studies have shown that patients with hepatocellular carcinoma and breast cancer who were on Medicaid or who were uninsured patients tended to have a more advanced stage at diagnosis and were more likely to refuse treatment after diagnosis \[[@b5-medscimonit-25-2397],[@b6-medscimonit-25-2397]\]. Also, insured patients with prostate cancer have been shown to have improved prognosis when compared to patients with Medicaid and uninsured individuals \[[@b7-medscimonit-25-2397]\]. However, there have been few previous studies on how insurance status impacts the stage at diagnosis, the definitive treatment, and the survival for patients with CRC, using population-based analysis \[[@b8-medscimonit-25-2397]\].

This study aimed to use data from the Surveillance, Epidemiology, and End Results (SEER) program \[[@b9-medscimonit-25-2397]\] to identify all patients with CRC who had specific insurance details and to analyze the effects of the stage at diagnosis, definitive treatment, and survival outcome, with insurance status.

Material and Methods
====================

Search strategy for the Surveillance, Epidemiology, and End Results (SEER) database
-----------------------------------------------------------------------------------

The Surveillance, Epidemiology, and End Results (SEER) database is a publicly available program composed of 18 cancer registries and covers approximately 30% of the population in the United States with a typical distribution \[[@b10-medscimonit-25-2397]\]. The data in the SEER database is de-identified to ensure patient confidentiality. The SEER database is considered to be representative of the entire US population, and includes patient demographic information and data from patient clinical records and follow-up data of survival. SEER is updated annually by the National Center for Health Statistics.

Permission was obtained to use the SEER database in November 2016 (Authorization number by Author QZT: 12738-Nov.2016). All the patient data were obtained through the SEER\*Stat software version 8.3.5 (released on March 6, 2018) (*<https://seer.cancer.gov/seerstat/>*), including demographic, clinical and follow-up information. Detailed information of the patients with CRC diagnosed between 2007 and 2009 from the SEER-18 was performed with SEER\*Stat software. This study complied with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Approval for this study was waived by the local ethics committee, and no informed consents were needed.

Inclusion criteria for patients with colorectal cancer (CRC) from the SEER database
-----------------------------------------------------------------------------------

All patients with colorectal cancer (CRC) were identified during 2007 and 2009 for analysis. The following study inclusion criteria were used: patients were included who were diagnosed with primary CRC, according to the Anatomic International Classification of Diseases for Oncology, Third Edition \[ICD-O-3\], codes C18.0, C18.1, C18.2, C18.3, C18.4, C18.5, C18.6, C18.7, C18.8, C18.9, C19.9, C20.9); patients were diagnosed between 2007 and 2009, because insurance status was missing in the database for patients diagnosed before 2007, and patients diagnosed after 2009 did not meet the 5-year follow-up period; patients included in the analysis were aged older than 18 years and younger than 85 years at diagnosis; patients were limited to adenocarcinoma (histologic ICD-O-3 codes: 8140, 8210, 8261, 8263, 8481), mucinous adenocarcinoma (histologic ICD-O-3 code: 8480), and signet ring cell carcinoma (histologic ICD-O-3 code: 8490).

The following study exclusion criteria were used: patients with unknown demographic information on gender, age at diagnosis, race, marital status, household income, college completion and rural/metropolitan location; patients with unknown clinical information including histologic grade, and AJCC TNM stage; patients with no information on definitive surgery or radiotherapy; patients with multiple primary tumors; patients with unknown cause of death or unknown survival time; patients with a survival time ≤1 month; autopsy or death certificate only.

Demographic data of patients with CRC from the SEER database
------------------------------------------------------------

Demographic data collected for analysis included gender, age, year of diagnosis, marital status, race, insurance status, household income, completion of college education, rural or metropolitan location, cancer site, histology, histologic grade, AJCC TNM stage, T status, N status, M status, surgical therapy, radiotherapy, chemotherapy, cause of death, and survival time (in months) from the SEER database. Gender was classified as male and female. The patients' ages were grouped as 18--54, 55--64, 65--74, and 75--85 years. The year of diagnosis was 2007, 2008, and 2009. Marital status was classified as married and unmarried. Race was classified as Asian/Pacific Islander, black, Hispanic white, and non-Hispanic white. Insurance status was classified as insured, Medicaid, and uninsured. Household income was classified into quartile 1 (\<59,080 dollars), quartile 2 (59,080--66,230 dollars), quartile 3 (55,230--83,950 dollars) and quartile 4 (\>83,950 dollars). College completion was classified into quartile 1 (\<17.22%), quartile 2 (17.22--24.86%), quartile 3 (24.86--30.51%) and quartile 4 (\>30.51%). Rural/metropolitan location was classified as rural and metropolitan.

Data on CRC from the SEER database
----------------------------------

Cancer site was classified as the left colon (splenic flexure, descending colon, sigmoid colon), the right colon (cecum, ascending colon, hepatic flexure, transverse colon), and rectosigmoid or the rectum (rectum, rectosigmoid junction). Histologic grade was classified as grade I, II, III, and IV. AJCC TNM stage was classified as stage I, II, III and IV. AJCC T status was classified as T1, T2, T3, and T4. AJCC N status was classified as N0, N1, N2, and N3. AJCC M status was classified as M0 and M1. SEER stage was classified as localized, regional and distant. Surgical treatment and radiotherapy were all defined as having received therapy or not. Chemotherapy was classified as having received chemotherapy or not/unknown. Definitive treatment was defined as receiving definitive surgery, radiotherapy or chemotherapy. Causes of death were classified as tumor cause-specific death (TCSD) and other cause-specific death (OCSD).

Statistical analysis
--------------------

The demographic, clinical, and pathologic features analyzed were summarized by descriptive statistical analysis. Continuous variables with normal distribution were described as the mean ± standard deviation (SD), continuous variables with skewed distribution were described as medians, first quartiles, and third quartiles, and categorical variables were described as frequencies and percentages. For categorical variables, Pearson's chi-squared (χ^2^) test and Fisher's exact tests were used to determine statistical significance. Multinomial logistic regression models were used to detect associations between insurance status and multifactor disease stage at diagnosis by R package of MASS, with the greater the odds ratio (OR) values, the more advanced the cancer stage. Binomial logistic regression models were used to detect associations between insurance status and definitive treatment, with the greater the OR values, the greater the possibility of receiving definitive treatment. Bar plots were drawn by R package of ggplot2. For tumor cause-specific survival (TCSS), deaths caused by CRC were considered as events. Kaplan-Meier analysis and the multivariate Cox proportional hazard model were selected to distinguish independent risk factors by the R package of KMsurv and survival. When displaying Kaplan-Meier curves based on raw data by the survminer R package, due to disequilibrium among different types of insurance, the curves were reproduced after propensity score matching (PSM) by R packages of MatchIt. In the competing risk analysis, OCSD was regarded as the competing event of TCSD. The Fine and Gray proportional sub-distribution hazard model was chosen to predict TCSD by R package cmprsk and riskRegression \[[@b11-medscimonit-25-2397],[@b12-medscimonit-25-2397]\]. All analysis was performed using R statistical software version 3.3.1 (released June 2016) (*[www.r-project.org](www.r-project.org)*). All P-values were two-sided and P\<0.05 was considered significant.

Results
=======

Baseline characteristics of patients with colorectal cancer (CRC) from the Surveillance, Epidemiology, and End Results (SEER) database
--------------------------------------------------------------------------------------------------------------------------------------

As shown in [Figure 1](#f1-medscimonit-25-2397){ref-type="fig"}, there were 54,232 patients with colorectal cancer (CRC) diagnosed between 2007 and 2009 in the Surveillance, Epidemiology, and End Results (SEER) database. Among these cases, 46,774 patients (86.2%) were insured, 5,651 patients (10.4%) had Medicaid, and 1,807 patients (3.3%) were uninsured. [Table 1](#t1-medscimonit-25-2397){ref-type="table"} showed the overall baseline characteristics of the patients and their insurance status. There were 28,798 male patients (53.1%), 32,777 married patients (60.4%), 37,696 non-Hispanic white patients (69.5%), and 47,269 patients who lived in metropolitan conditions (87.2%). Analysis of the clinicopathological data showed that the majority of patients, 50,353, had a colorectal adenocarcinoma (92.8%), of which, 39,484 were grade II (72.8%), 16,866 were AJCC stage III (31.1%), 30,181 were T3 (55.7%), 31,282 were N0 (57.7%), 46,361 were M0 (57.7%) and 23,160 were SEER regional stage (42.7%). There were 52,215 patients (96.3%) who received surgical treatment, 8,588 patients (15.8%) receiving radiotherapy, and 23,929 patients (44.1%) received chemotherapy. The median follow-up period was 66.0 months (range, 36.0--80.0 months).

Cancer stage at diagnosis
-------------------------

As shown in [Figure 2](#f2-medscimonit-25-2397){ref-type="fig"}, insured patients were more likely to have an earlier SEER stage at diagnosis when compared with Medicaid or uninsured patients. However, uninsured patients had the lowest proportion of SEER localized stage, as well as the highest proportion of SEER distant stage. Univariate analysis, shown in [Table 2](#t2-medscimonit-25-2397){ref-type="table"}, identified sociodemographic factors associated with SEER stage at diagnosis, including age group, marital status, race, insurance status, income, and education. After adjusting the multivariate logistic analysis, insurance status was still an independent influencing factor of SEER stage. Insured patients had an earlier SEER stage at diagnosis compared with other patients, including patients with Medicaid compared with insured patients (adjusted OR, 1.318; 95% CI, 1.249--1.391) and uninsured patients compared with insured patients (adjusted OR, 1.479; 95% CI, 1.352--1.618 P\<0.001). Married patients and non-Hispanic white patients were diagnosed at an early stage, with unmarried compared with married patients (adjusted OR, 1.110; 95% CI, 1.073--1.148; P\<0.001) and non-Hispanic white patients compared with Asian/Pacific Islanders (adjusted OR, 0.896; 95% CI, 0.846--0.949; P\<0.001). [Supplementary Table 1](#s1-medscimonit-25-2397){ref-type="supplementary-material"} showed the findings of the impact of insurance status on SEER stage stratified by age group, race, or cancer site, which showed that insured patients had an earlier stage at diagnosis. [Table 3](#t3-medscimonit-25-2397){ref-type="table"} showed the association between insurance status and AJCC stage, T status, N status and M status stratified by cancer site after changing the response variables in the multivariate logistic models. Finally, insured patients were found to be significantly more likely to be diagnosed with an earlier cancer stage and TNM status when compared with Medicaid or uninsured patients.

Definitive treatment
--------------------

[Figure 3](#f3-medscimonit-25-2397){ref-type="fig"} showed that insured patients were more likely to receive definitive treatment when compared with Medicaid or uninsured patients. The chi-squared analysis data shown in [Table 4](#t4-medscimonit-25-2397){ref-type="table"} summarized the sociodemographic and clinical factors associated with definitive treatment, including gender, age group, marital status, race, insurance status, income, education, residence, cancer site, and SEER stage. After adjustment in the multivariate analysis, insurance status remained as a significant relevant factor of definitive treatment. The insured patient group tended to receive definitive treatment when compared with Medicaid (adjusted OR, 0.591; 95% CI, 0.470--0.742; P\<0.001) and uninsured patients (adjusted OR, 0.404; 95% CI, 0.282--0.579; P\<0.001). Unmarried, black, or rural patients were more likely to refuse definitive treatment (unmarried *vs.* married, adjusted OR, 0.634; 95% CI, 0.531--0.757; P\<0.001) (black *vs.* Asian/Pacific Islander, adjusted OR, 0.558; 95% CI, 0.379--0.823; P=0.003) (rural *vs.* metropolitan, adjusted OR, 0.723; 95% CI, 0.557--0.938; P=0.015). As shown in [Supplementary Table 2](#s2-medscimonit-25-2397){ref-type="supplementary-material"}, to reduce the bias among groups, a subgroup analysis stratified by age group, race or cancer site, and showed that the impact of insurance status on definitive treatment persisted, in most cases.

Tumor cause-specific survival (TCSS)
------------------------------------

As shown in [Supplementary Table 3](#s3-medscimonit-25-2397){ref-type="supplementary-material"}, the 3-year and 5-year TCSS rates were 81.92% and 74.91% in the insured group, 72.71% and 63.46% in the Medicaid group, and 74.36% and 64.85% in the uninsured group, respectively. As shown in [Table 5](#t5-medscimonit-25-2397){ref-type="table"}, Cox analysis adjusted all the significant prognostic factors detected by univariate Kaplan-Meier analysis and showed that insurance status remained as an independent prognostic factor for tumor cause-specific survival (TCSS). Insured patients had a significantly increased TCSS when compared with patients receiving Medicaid (HR, 1.298; 95% CI, 1.236--1.363; P\<0.001) and compared with patients who were uninsured (HR 1.195, 95% CI, 1.100--1.297; P\<0.001). Kaplan-Meier survival curves shown in [Figure 4](#f4-medscimonit-25-2397){ref-type="fig"}, demonstrated that the prognosis of the insured group was significantly better than that of the other two groups when using the raw data. After the adjustment of propensity score matching (PSM) ([Supplementary Table 4](#s4-medscimonit-25-2397){ref-type="supplementary-material"}), the effect of the insured group still existed with the balancing data as shown in [Figure 4B](#f4-medscimonit-25-2397){ref-type="fig"}. Following the Fine and Gray analysis, insurance status remained as an independent predictive factor of TCSS. Medicaid or uninsured individuals had significantly worse prognosis when compared with insured patients. Medicaid patients compared with insured patients (sub-distribution HR, 1.260; 95% CI, 1.192--1.332; P\<0.001), uninsured patients compared with insured patients (sub-distribution HR 1.195; 95% CI, 1.041--1.256; P=0.005). As shown in [Figure 5](#f5-medscimonit-25-2397){ref-type="fig"}, the patients were stratified by age group, race, and cancer site, which showed that insured patients always had the best TCSS outcomes.

Discussion
==========

A retrospective cohort study used data from the Surveillance, Epidemiology, and End Results (SEER) database, and investigated the influence of insurance status on the disease stage at diagnosis, the definitive treatment, and the survival outcome in 54,232 patients with colorectal cancer (CRC). Among these patients, 86.2% were insured, 10.4% had Medicaid, and 3.3% were uninsured. Insurance status was a significant influencing factor of SEER stage. The SEER stage at diagnosis in Medicaid or uninsured patients was more advanced than insured patients. Insured patients had significantly earlier cancer stage and TNM status. As for definitive treatment, insurance status remained as a relevant factor, and insured patients were more likely to receive definitive treatment when compared with Medicaid or uninsured patients. Also, in terms of prognosis, the 5-year tumor cause-specific survival (TCSS) rates were 74.91% in the insured group, 63.46% in the Medicaid group, and 64.85% in the uninsured group. Both the Cox regression model and the Fine and Gray model showed that insurance status was an independent prognostic factor for TCSS. Insured patients had a better prognosis than either Medicaid or uninsured patients.

Socioeconomic factors, including household income, education level, and marital status, have previously been confirmed to affect tumor prognosis \[[@b13-medscimonit-25-2397]--[@b16-medscimonit-25-2397]\]. CRC is the third most common cancer and the third leading cause of cancer death in the United States. However, the relationship between CRC and insurance status has not been previously studied in detail. In the present study, insurance status was found to be an independent predictive factor for disease stage, definitive treatment, and prognosis, which is consistent with the findings from previous studies in other cancers \[[@b6-medscimonit-25-2397]\]. Tantraworasin et al. studied the effect of insurance type in Asian patients with lung cancer and found that uninsured or Medicaid Asian patients were more likely to be diagnosed with advanced disease, less likely to undergo treatment, and had shorter overall survival \[[@b17-medscimonit-25-2397]\]. Similar results have been found for hepatocellular carcinoma and prostate cancer \[[@b5-medscimonit-25-2397],[@b7-medscimonit-25-2397]\]. In 2016, Rima et al. identified the association between race and insurance in patients with CRC, with similar findings to those of the present study, but only took into account limited patient demographic data, including only age, sex, race, marital status and insurance, probably due to problems with data acquisition \[[@b18-medscimonit-25-2397]\]. The present study analyzed more variables, including income, education, residence or cancer site, to adjust for the complicated effects, and included stratified analysis to reduce bias, and adopted reasonable multinomial logistic models to detect the association between insurance and cancer stage \[[@b8-medscimonit-25-2397]\]. However, in this stratified analysis, the effect of insurance status was not statistically significant in the subgroup aged more than 65 years. This finding may have been because the numbers of uninsured persons in those subgroups were less than 100, resulting in less adequate sample sizes \[[@b17-medscimonit-25-2397]\].

There are other potential reasons for the impact of insurance on the cancer stage at diagnosis. The results of this study showed that insured patients tended to be initially diagnosed at an early stage, probably because these patients were more likely to attend regular medical screening appointments and procedures, including colonoscopies or computed tomography (CT) colonography \[[@b4-medscimonit-25-2397],[@b19-medscimonit-25-2397],[@b20-medscimonit-25-2397]\]. Therefore, CRC can be found at an earlier stage in insured patients \[[@b21-medscimonit-25-2397]\]. CRC screening rates have increased between 2008 to 2015 in the United States, but the uninsured patient population continues to be screened for cancer at below the recommended levels \[[@b22-medscimonit-25-2397]\].

The disparities between treatment in Medicaid or uninsured patients compared with insured patients have been previously reported \[[@b23-medscimonit-25-2397],[@b24-medscimonit-25-2397]\]. In this study, the majority of patients with CRC received definitive treatment during the follow-up period, but the possibility of insured patients receiving treatment was significantly increased when compared with other patient groups. This finding may be because healthcare organizations preferentially admit, diagnose, and treat insured patients instead of Medicaid or uninsured patients \[[@b25-medscimonit-25-2397]\]. Also, low income and weak social networks, which may be relevant factors of Medicaid or uninsured status, strongly hamper treatment \[[@b26-medscimonit-25-2397]\]. Because of high treatment costs, uninsured patients may not seek treatment or screening for early diagnosis due to inability to pay the healthcare costs.

The differences in prognosis and patient survival among the patient groups with CRC and different insurance status were closely related to cancer stage and treatment. The data analyzed in this study demonstrated that uninsured or Medicaid patients were probably diagnosed at a more advanced stage, resulting in a worse survival outcome. Also, these patients tend to refuse definitive treatment, which also results in a poor prognosis. In this study, propensity score matching (PSM) was used to balance baseline variance among groups, and insured patients remained as having the optimal prognosis using Kaplan-Meier analysis. The traditional Kaplan-Meier analysis and Cox regression analysis often overestimate the risk of the tested event, which is overcome by the Fine and Gray proportional sub-distribution hazard analysis \[[@b27-medscimonit-25-2397]\]. In this study, the Fine and Gray model was used to correct the hazard of predictive factors. Therefore, even if the effect of insurance status on prognosis was reduced by the Fine and Gray competing risk model, the results were still statistically significant.

Globally, human cancer results in a large medical and socioeconomic burden. The significance of the findings of this study indicates that medical insurance coverage should increase as part of healthcare reform to ensure that individuals have health insurance. Only in this way can the early diagnosis of cancer, including CRC, treatments, and prognosis be improved. In the USA, the government initiated Medicaid for partial uninsured individuals or minorities with low incomes and low education levels \[[@b28-medscimonit-25-2397]\]. The original intention of Medicaid was to protect the insurance benefits of vulnerable groups and reduce the racial and socioeconomic imbalance in health care \[[@b7-medscimonit-25-2397],[@b28-medscimonit-25-2397]\]. However, according to the findings of this study, no significant difference was detected in TCSS between Medicaid and uninsured patients with CRC. The Medicaid patients had even more adverse survival outcomes than uninsured patients, after PSM. Therefore, whether it is a developed or developing country, expanding the coverage of medical insurance will be an important measure for government healthcare reform \[[@b26-medscimonit-25-2397]\]. For CRC, private insurance for high-income individuals, and increasing the prevalence of Medicaid for low-income individuals, with the encouragement of screening programs using colonoscopy is recommended.

This study had several limitations. During the screening process of the SEER database, more than half of the original identified 100,000 patients were excluded, because of missing demographic, clinical and pathologic information, which might have resulted in selection bias. Some risk factors, including smoking status, alcohol use, medical comorbidities, and clinical complications, can affect the diagnosis, treatment and survival of patients with CRC. However, the SEER program did not collect these data for the target population. Also, the variables of household income and education level provided by the SEER database are not at patient-level, but at regional level. Detailed therapeutic regimens, including the use of specific chemotherapy, were not directly available from the SEER database, which was a limitation of the study, as chemotherapy has become a routine treatment for patients with advanced CRC. Insurance status, as the key variable, has been in the SEER database since 2007, but only consists of insured, Medicaid, and uninsured status. However, even insured status might be subdivided into private insurance, government Medicare, and coverage from the military or Veterans Affairs, which were inaccessible in the SEER database. The disparities among these different insurance states should be investigated in future studies. Also, given that this was a retrospective cohort study, based on the statistical methods, it was only possible to demonstrate correlations, instead of causality, between insurance status and cancer stage as well as definitive treatment. It is not possible to determine whether insured patients had an earlier cancer stage at diagnosis and inevitably received definitive treatment, and further studies are needed.

Conclusions
===========

A large population-based analysis of patients with colorectal cancer (CRC) used data from the Surveillance, Epidemiology, and End Results (SEER) database. Insurance status was a significant factor that determined early diagnosis, definitive treatment, and was an independent factor for tumor cause-specific survival (TCSS) in patients with CRC. Insured patients had a significantly earlier cancer stage at diagnosis, were significantly more likely to receive definitive treatment, and had a better prognosis than either patients with Medicaid or uninsured patients. In the USA, increased health insurance coverage may facilitate early diagnosis, promote definitive treatment, and improve the outcome for patients with CRC.

Supplementary Tables
====================

###### 

Adjusted odds ratios (OR) for impact of insurance status on the Surveillance, Epidemiology and End Results (SEER) stage, stratified by age group, race or cancer site.

  Subgroup                  Insurance status (versus Insured)   Adjusted OR    95% CI         P-value
  ------------------------- ----------------------------------- -------------- -------------- ---------
  Age group (years)                                                                           
   18--54                   Medicaid                            1.642          1.476--1.827   \<0.001
  Uninsured                 1.447                               1.266--1.655                  
   55--64                   Medicaid                            1.466          1.315--1.635   \<0.001
  Uninsured                 1.540                               1.346--1.762                  
   65--74                   Medicaid                            1.142          1.030--1.266   0.005
  Uninsured                 1.547                               1.544--1.549                  
   75--85                   Medicaid                            1.051          0.936--1.179   0.578
  Uninsured                 1.192                               1.191--1.193                  
  Race                                                                                        
   Asian/Pacific Islander   Medicaid                            1.387          1.203--1.599   \<0.001
  Uninsured                 1.702                               1.668--1.736                  
   Black                    Medicaid                            1.318          1.160--1.497   \<0.001
  Uninsured                 1.380                               1.145--1.664                  
   Hispanic white           Medicaid                            1.335          1.179--1.511   \<0.001
  Uninsured                 1.138                               1.052--1.231                  
   Non-Hispanic white       Medicaid                            1.295          1.199--1.398   \<0.001
  Uninsured                 1.614                               1.595--1.633                  
  Site                                                                                        
   Left colon               Medicaid                            1.385          1.262--1.519   \<0.001
  Uninsured                 1.566                               1.532--1.601                  
   Right colon              Medicaid                            1.188          1.090---.295   \<0.001
  Uninsured                 1.343                               1.332--1.353                  
   Rectosigmoid/Rectum      Medicaid                            1.428          1.294--1.575   \<0.001
  Uninsured                 1.558                               1.525--1.592                  

SEER -- the Surveillance, Epidemiology and End Results; OR -- odds ratio; CI -- confidence interval. Multivariable logistic models were adjusted for age group, gender, year of diagnosis, marriage, race, household income, college completion, residence and cancer site.

###### 

Adjusted odds ratios (ORs) for the impact of insurance status on definitive treatment stratified by age group, race, or cancer site.

  Subgroup                  Insurance status (versus Insured)   Adjusted OR    95% CI         P-value
  ------------------------- ----------------------------------- -------------- -------------- ---------
  Age group (years)                                                                           
   18--54                   Medicaid                            0.433          0.254--0.741   0.002
  Uninsured                 0.304                               0.171--0.543   \<0.001        
   55--64                   Medicaid                            0.372          0.229--0.603   \<0.001
  Uninsured                 0.391                               0.218--0.703   0.002          
   65--74                   Medicaid                            0.638          0.396--1.027   0.064
  Uninsured                 0.549                               0.124--2.436   0.431          
   75--85                   Medicaid                            0.839          0.559--1.260   0.398
  Uninsured                 0.340                               0.101--1.143   0.081          
  Race                                                                                        
   Asian/Pacific Islander   Medicaid                            0.610          0.288--1.291   0.196
  Uninsured                 0.213                               0.065--0.700   0.011          
   Black                    Medicaid                            0.492          0.311--0.776   0.002
  Uninsured                 0.265                               0.142--0.495   \<0.001        
   Hispanic white           Medicaid                            0.734          0.426--1.265   0.266
  Uninsured                 0.679                               0.254--1.817   0.441          
   Non-Hispanic white       Medicaid                            0.589          0.420--0.826   0.002
  Uninsured                 0.480                               0.271--0.850   0.012          
  Canser site                                                                                 
   Left colon               Medicaid                            0.646          0.402--1.037   0.070
  Uninsured                 0.510                               0.235--1.108   0.089          
   Right colon              Medicaid                            0.567          0.409--0.786   \<0.001
  Uninsured                 0.438                               0.258--0.743   0.002          
   Rectosigmoid/Rectum      Medicaid                            0.577          0.372--0.895   0.014
  Uninsured                 0.287                               0.151--0.548   \<0.001        

OR -- odds ratio; CI -- confidence interval. Multivariable logistic models were adjusted for age group, gender, marriage, race, household income, college completion, residence, cancer site, histology and the Surveillance, Epidemiology and End Results (SEER) stage.

###### 

Univariate survival analysis for tumor cause-specific survival in patients with colorectal cancer.

  Characteristics               3-year   5-year   Log rank   P-value
  ----------------------------- -------- -------- ---------- ---------
  Gender                                          4          0.045
   Female                       80.70%   73.87%              
   Male                         80.75%   73.01%              
  Age group (years)                               134        \<0.001
   18--54                       81.50%   73.41%              
   55--64                       82.55%   75.04%              
   65--74                       81.68%   75.09%              
   75--85                       77.18%   70.02%              
  Year of diagnosis                               2          0.365
   2007                         80.75%   73.42%              
   2008                         80.41%   73.10%              
   2009                         81.02%   73.73%              
  Marital status                                  284        \<0.001
   Married                      82.81%   75.91%              
   Unmarried                    77.50%   69.50%              
  Race                                            200        \<0.001
   Asian/Pacific Islander       82.50%   74.97%              
   Black                        74.99%   66.35%              
   Hispanic white               81.06%   73.19%              
   Non-Hispanic white           81.43%   74.45%              
  Insurance status                                436        \<0.001
   Insured                      81.92%   74.91%              
   Medicaid                     72.71%   63.46%              
   Uninsured                    74.36%   64.85%              
  Income                                          84.1       \<0.001
   Quartile 1                   82.53%   75.47%              
   Quartile 2                   81.31%   74.13%              
   Quartile 3                   80.31%   73.00%              
   Quartile 4                   78.63%   70.89%              
  Education                                       58.9       \<0.001
   Quartile 1                   82.11%   74.97%              
   Quartile 2                   81.33%   74.40%              
   Quartile 3                   79.87%   72.26%              
   Quartile 4                   79.30%   71.63%              
  Residence                                       20.1       \<0.001
   Metropolitan                 80.94%   73.69%              
   Rural                        79.27%   71.51%              
  Cancer site                                     42.4       \<0.001
   Left colon                   82.70%   75.03%              
   Right colon                  79.05%   73.28%              
   Rectosigmoid/rectum          81.11%   71.97%              
  Histology                                       434        \<0.001
   Adenocarcinoma               81.38%   74.07%              
   Mucinous adenocarcinoma      75.22%   67.88%              
   Signet ring cell carcinoma   48.28%   40.94%              
  Grade                                           1577       \<0.001
   I                            90.17%   85.20%              
   II                           83.03%   75.47%              
   III                          67.06%   59.66%              
   IV                           65.93%   57.70%              
  AJCC stage                                      25127      \<0.001
   I                            96.35%   93.66%              
   II                           91.08%   85.73%              
   III                          80.37%   70.88%              
   IV                           33.08%   18.41%              
  AJCC-T                                          6734       \<0.001
   T1                           91.38%   88.19%              
   T2                           94.34%   90.79%              
   T3                           79.74%   71.06%              
   T4                           53.28%   41.76%              
  AJCC-N                                          8891       \<0.001
   N0                           90.53%   85.83%              
   N1                           75.96%   66.75%              
   N2                           54.93%   41.79%              
  AJCC-M                                          23177      \<0.001
   M0                           88.77%   82.70%              
   M1                           33.08%   18.41%              
  SEER stage                                      23652      \<0.001
   Localized                    95.06%   91.50%              
   Regional                     83.35%   74.99%              
   Distant                      35.37%   20.99%              
  Surgery                                         3945       \<0.001
   Yes                          82.37%   75.11%              
   No                           35.71%   26.47%              
  Radiotherapy                                    2353       \<0.001
   Yes                          73.77%   63.15%              
   No                           86.39%   81.88%              
  Chemotherapy                                    114        \<0.001
   Yes                          79.50%   69.01%              
   No                           80.96%   74.27%              

TCSS -- tumor cause-specific survival; AJCC -- the American Joint Committee on Cancer; SEER -- the Surveillance, Epidemiology and End Results.

###### 

Baseline characteristics by insurance status in patients with colorectal cancer after propensity score matching (PSM).

  Characteristic                Insured       Medicaid      Uninsured     P-value
  ----------------------------- ------------- ------------- ------------- ---------
  Gender                                                                  0.872
   Male                         999 (55.7)    973 (54.8)    982 (55.3)    
   Female                       796 (44.3)    803 (45.2)    794 (44.7)    
  Age group (years)                                                       0.857
   18--54                       858 (47.8)    828 (46.6)    836 (47.1)    
   55--64                       797 (44.4)    809 (45.6)    800 (45.0)    
   65--74                       80 (4.5)      91 (5.1)      87 (4.9)      
   75--85                       60 (3.3)      48 (2.7)      53 (3.0)      
  Year of diagnosis                                                       0.710
   2007                         579 (32.3)    548 (30.9)    580 (32.7)    
   2008                         613 (34.2)    602 (33.9)    585 (32.9)    
   2009                         603 (33.6)    626 (35.2)    611 (34.4)    
  Marital status                                                          
   Married                      784 (43.7)    738 (41.6)    743 (41.8)    0.378
   Unmarried                    1011 (56.3)   1038 (58.4)   1033 (58.2)   
  Race                                                                    0.988
   Asian/Pacific Islander       156 (8.7)     157 (8.8)     149 (8.4)     
   Black                        416 (23.2)    423 (23.8)    430 (24.2)    
   Hispanic white               330 (18.4)    323 (18.2)    315 (17.7)    
   Non-Hispanic white           893 (49.7)    873 (49.2)    882 (49.7)    
  Household income                                                        0.907
   Quartile 1                   274 (15.3)    259 (14.6)    261 (14.7)    
   Quartile 2                   401 (22.3)    376 (21.2)    382 (21.5)    
   Quartile 3                   482 (26.9)    506 (28.5)    484 (27.3)    
   Quartile 4                   638 (35.5)    635 (35.8)    649 (36.5)    
  College completion                                                      0.712
   Quartile 1                   360 (20.1)    336 (18.9)    343 (19.3)    
   Quartile 2                   473 (26.4)    509 (28.7)    490 (27.6)    
   Quartile 3                   356 (19.8)    366 (20.6)    354 (19.9)    
   Quartile 4                   606 (33.8)    565 (31.8)    589 (33.2)    
  Rural/metropolitan location                                             0.924
   Rural                        288 (16.0)    286 (16.1)    293 (16.5)    
   Metropolitan                 1507 (84.0)   1490 (83.9)   1483 (83.5)   
  Cancer site                                                             0.938
   Left colon                   644 (35.9)    639 (36.0)    618 (34.8)    
   Right colon                  605 (33.7)    589 (33.2)    603 (34.0)    
   Rectosigmoid/rectum          546 (30.4)    548 (30.9)    555 (31.2)    
  Histology                                                               0.932
   Adenocarcinoma               1671 (93.1)   1646 (92.7)   1645 (92.6)   
   Mucinous adenocarcinoma      111 (6.2)     113 (6.4)     114 (6.4)     
   Signet ring cell carcinoma   13 (0.7)      17 (1.0)      17 (1.0)      
  Grade                                                                   0.870
   I                            146 (8.1)     140 (7.9)     135 (7.6)     
   II                           1315 (73.3)   1330 (74.9)   1321 (74.4)   
   III                          294 (16.4)    269 (15.1)    288 (16.2)    
   IV                           40 (2.2)      37 (2.1)      32 (1.8)      
  AJCC stage                                                              0.663
   I                            248 (13.8)    263 (14.8)    261 (14.7)    
   II                           568 (31.6)    514 (28.9)    522 (29.4)    
   III                          601 (33.5)    624 (35.1)    609 (34.3)    
   IV                           378 (21.1)    375 (21.1)    384 (21.6)    
  AJCC-T                                                                  0.603
   T1                           159 (8.9)     180 (10.1)    181 (10.2)    
   T2                           163 (9.1)     155 (8.7)     164 (9.2)     
   T3                           1106 (61.6)   1050 (59.1)   1064 (59.9)   
   T4                           367 (20.4)    391 (22.0)    367 (20.7)    
  AJCC-N                                                                  0.668
   N0                           913 (50.9)    865 (48.7)    881 (49.6)    
   N1                           511 (28.5)    514 (28.9)    502 (28.3)    
   N2                           371 (20.7)    397 (22.4)    393 (22.1)    
  AJCC-M                                                                  0.903
   M0                           1417 (78.9)   1401 (78.9)   1392 (78.4)   
   M1                           378 (21.1)    375 (21.1)    384 (21.6)    
  SEER stage                                                              0.946
   Localized                    541 (30.1)    518 (29.2)    529 (29.8)    
   Regional                     839 (46.7)    837 (47.1)    821 (46.2)    
   Distant                      415 (23.1)    421 (23.7)    426 (24.0)    
  Surgery                                                                 0.355
   Yes                          1675 (93.3)   1646 (92.7)   1635 (92.1)   
   No                           120 (6.7)     130 (7.3)     141 (7.9)     
  Radiotherapy                                                            0.446
   Yes                          366 (20.4)    379 (21.3)    393 (22.1)    
   No                           1429 (79.6)   1397 (78.7)   1383 (77.9)   
  Chemotherapy                                                            0.725
   Yes                          1071 (59.7)   1071 (60.3)   1083 (61.0)   
   No                           724 (40.3)    705 (39.7)    693 (39.0)    

N -- number; AJCC -- the American Joint Committee on Cancer; SEER -- the Surveillance, Epidemiology and End Results.
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###### 

Baseline characteristics of included patients with colorectal cancer, overall and by insurance status.

  Characteristic                Overall        Insured        Medicaid      Uninsured
  ----------------------------- -------------- -------------- ------------- -------------
  Gender                                                                    
   Male                         28798 (53.1)   25117 (53.7)   2676 (47.4)   1005 (55.6)
   Female                       25434 (46.9)   21657 (46.3)   2975 (52.6)   802 (44.4)
  Age (years)                   64.42±12.58    65.00±12.43    62.85±13.06   54.36±9.74
  Age group (years)                                                         
   18--54                       12504 (23.1)   10139 (21.7)   1521 (26.9)   844 (46.7)
   55--64                       13328 (24.6)   11098 (23.7)   1407 (24.9)   823 (45.5)
   65--74                       14585 (26.9)   12993 (27.8)   1505 (26.6)   87 (4.8)
   75--85                       13815 (25.5)   12544 (26.8)   1218 (21.6)   53 (2.9)
  Year of diagnosis                                                         
   2007                         18317 (33.8)   15926 (34.0)   1801 (31.9)   590 (32.7)
   2008                         18060 (33.3)   15607 (33.4)   1856 (32.8)   597 (33.0)
   2009                         17855 (32.9)   15241 (32.6)   1994 (35.3)   620 (34.3)
  Marital status                                                            
   Married                      32777 (60.4)   29911 (63.9)   2095 (37.1)   771 (42.7)
   Unmarried                    21455 (39.6)   16863 (36.1)   3556 (62.9)   1036 (57.3)
  Race                                                                      
   Asian/Pacific Islander       4689 (8.6)     3675 (7.9)     865 (15.3)    149 (8.2)
   Black                        6427 (11.9)    4902 (10.5)    1085 (19.2)   440 (24.3)
   Hispanic white               5420 (10.0)    3953 (8.5)     1152 (20.4)   315 (17.4)
   Non-Hispanic white           37696 (69.5)   34244 (73.2)   2549 (45.1)   903 (50.0)
  Household income                                                          
   Quartile 1                   13873 (25.6)   12507 (26.7)   1104 (19.5)   262 (14.5)
   Quartile 2                   13393 (24.7)   12045 (25.8)   948 (16.8)    400 (22.1)
   Quartile 3                   13991 (25.8)   11591 (24.8)   1915 (33.9)   485 (26.8)
   Quartile 4                   12975 (23.9)   10631 (22.7)   1684 (29.8)   660 (36.5)
  College completion                                                        
   Quartile 1                   13890 (25.6)   12449 (26.6)   1085 (19.2)   356 (19.7)
   Quartile 2                   15496 (28.6)   12992 (27.8)   2011 (35.6)   493 (27.3)
   Quartile 3                   11483 (21.2)   10151 (21.7)   971 (17.2)    361 (20.0)
   Quartile 4                   13363 (24.6)   11182 (23.9)   1584 (28.0)   597 (33.0)
  Rural/metropolitan location                                               
   Rural                        6963 (12.8)    5894 (12.6)    773 (13.7)    296 (16.4)
   Metropolitan                 47269 (87.2)   40880 (87.4)   4878 (86.3)   1511 (83.6)
  Cancer site                                                               
   Left colon                   16243 (30.0)   13776 (29.5)   1835 (32.5)   632 (35.0)
   Right colon                  22669 (41.8)   19944 (42.6)   2110 (37.3)   615 (34.0)
   Rectosigmoid/rectum          15320 (28.2)   13054 (27.9)   1706 (30.2)   560 (31.0)
  Histology                                                                 
   Adenocarcinoma               50353 (92.8)   43435 (92.9)   5242 (92.8)   1676 (92.8)
   Mucinous adenocarcinoma      3434 (6.3)     2957 (6.3)     363 (6.4)     114 (6.3)
   Signet ring cell carcinoma   445 (0.8)      382 (0.8)      46 (0.8)      17 (0.9)
  Grade                                                                     
   I                            4790 (8.8)     4207 (9.0)     445 (7.9)     138 (7.6)
   II                           39484 (72.8)   33918 (72.5)   4218 (74.6)   1348 (74.6)
   III                          9135 (16.8)    7933 (17.0)    913 (16.2)    289 (16.0)
   IV                           823 (1.5)      716 (1.5)      75 (1.3)      32 (1.8)
  AJCC stage                                                                
   I                            14054 (25.9)   12696 (27.1)   1095 (19.4)   263 (14.6)
   II                           15441 (28.5)   13212 (28.2)   1698 (30.0)   531 (29.4)
   III                          16866 (31.1)   14444 (30.9)   1797 (31.8)   625 (34.6)
   IV                           7871 (14.5)    6422 (13.7)    1061 (18.8)   388 (21.5)
  AJCC-T                                                                    
   T1                           8976 (16.6)    8065 (17.2)    728 (12.9)    183 (10.1)
   T2                           8444 (15.6)    7599 (16.2)    681 (12.1)    164 (9.1)
   T3                           30181 (55.7)   25775 (55.1)   3319 (58.7)   1087 (60.2)
   T4                           6631 (12.2)    5335 (11.4)    923 (16.3)    373 (20.6)
  AJCC-N                                                                    
   N0                           31282 (57.7)   27286 (58.3)   3104 (54.9)   892 (49.4)
   N1                           13582 (25.0)   11615 (24.8)   1450 (25.7)   517 (28.6)
   N2                           9368 (17.3)    7873 (16.8)    1097 (19.4)   398 (22.0)
  AJCC-M                                                                    
   M0                           46361 (85.5)   40352 (86.3)   4590 (81.2)   1419 (78.5)
   M1                           7871 (14.5)    6422 (13.7)    1061 (18.8)   388 (21.5)
  SEER stage                                                                
   Localized                    22571 (41.6)   20047 (42.9)   1991 (35.2)   533 (29.5)
   Regional                     23160 (42.7)   19814 (42.4)   2502 (44.3)   844 (46.7)
   Distant                      8501 (15.7)    6913 (14.8)    1158 (20.5)   430 (23.8)
  Surgery                                                                   
   Yes                          52215 (96.3)   45252 (96.7)   5299 (93.8)   1664 (92.1)
   No                           2017 (3.7)     1522 (3.3)     352 (6.2)     143 (7.9)
  Radiotherapy                                                              
   Yes                          8588 (15.8)    7179 (15.3)    1012 (17.9)   397 (22.0)
   No                           45644 (84.2)   39595 (84.7)   4639 (82.1)   1410 (78.0)
  Chemotherapy                                                              
   Yes                          23929 (44.1)   20242 (43.3)   2576 (45.6)   1111 (61.5)
   No                           30303 (55.9)   26532 (56.7)   3075 (54.4)   696 (38.5)

N -- number; AJCC -- the American Joint Committee on Cancer; SEER -- the Surveillance, Epidemiology and End Results.

###### 

Multivariate logistic regression analysis of the association between the Surveillance, Epidemiology and End Results (SEER) stage at diagnosis and sociodemographic factors, including insurance status.

  Characteristic            Univariate analysis   Multivariate analysis                                               
  ------------------------- --------------------- ----------------------- ------ --------- ----------- -------------- ---------
  Gender                                                                                                              
   Male                     12044                 12194                   4560   0.175                                
   Female                   10527                 10966                   3941                                        
  Age group (years)                                                              \<0.001                              \<0.001
   18--54                   4327                  5633                    2544             Reference                  
   55--64                   5420                  5638                    2270             0.781       0.746--0.818   
   65--74                   6469                  6042                    2074             0.668       0.638--0.700   
   75--85                   6355                  5847                    1613             0.599       0.571--0.628   
  Year of diagnosis                                                              0.114                                
   2007                     7532                  7957                    2828                                        
   2008                     7510                  7691                    2859                                        
   2009                     7529                  7512                    2814                                        
  Marital status                                                                 \<0.001                              \<0.001
   Married                  14004                 13826                   4947             Reference                  
   Unmarried                8567                  9334                    3554             1.110       1.073--1.148   
  Race                                                                           \<0.001                              \<0.001
   Asian/Pacific Islander   1790                  2134                    765              Reference                  
   Black                    2491                  2705                    1231             0.976       0.908--1.049   
   Hispanic white           2112                  2418                    890              0.938       0.871--1.009   
   Non-Hispanic white       16178                 15903                   5615             0.896       0.846--0.949   
  Insurance status                                                               \<0.001                              \<0.001
   Insured                  20047                 19814                   6913             Reference                  
   Medicaid                 1991                  2502                    1158             1.318       1.249--1.391   
   Uninsured                533                   844                     430              1.479       1.352--1.618   
  Income                                                                         0.001                                
   Quartile 1               5781                  6012                    2080                                        
   Quartile 2               5637                  5748                    2008                                        
   Quartile 3               5793                  5946                    2252                                        
   Quartile 4               5360                  5454                    2161                                        
  Education                                                                      0.02                                 
   Quartile 1               5735                  6051                    2104                                        
   Quartile 2               6470                  6636                    2390                                        
   Quartile 3               4726                  4917                    1840                                        
   Quartile 4               5640                  5556                    2167                                        
  Residence                                                                      0.294                                
   Rural                    2866                  2962                    1135                                        
   Metropolitan             19705                 20198                   7366                                        
  Cancer site                                                                    \<0.001                              \<0.001
   Left colon               6634                  6800                    2809             Reference                  
   Right colon              9533                  9564                    3572             1.010       0.971--1.050   
   Rectosigmoid/rectum      6404                  6796                    2120             0.892       0.855--0.930   

SEER -- the Surveillance, Epidemiology and End Results; OR -- odds ratio; CI -- confidence interval.

###### 

Multivariate logistic regression models evaluating the impact of insurance status on AJCC stage, T status, N status and M status stratified by cancer site in patients with colorectal cancer.

  Cancer site           Response variable   Insurance status (versus Insured)   Adjusted OR    95% CI         P-value
  --------------------- ------------------- ----------------------------------- -------------- -------------- ---------
  Left colon            AJCC stage          Medicaid                            1.359          1.244--1.484   \<0.001
  Uninsured             1.494               1.461--1.527                                                      
  AJCC-T                Medicaid            1.570                               1.426--1.728   \<0.001        
  Uninsured             2.159               2.113--2.206                                                      
  AJCC-N                Medicaid            1.173                               1.066--1.291   \<0.001        
  Uninsured             1.208               1.179--1.237                                                      
  AJCC-M                Medicaid            1.326                               1.160--1.515   \<0.001        
  Uninsured             1.393               1.139--1.704                                                      
  Right colon           AJCC stage          Medicaid                            1.168          1.076--1.269   \<0.001
  Uninsured             1.375               1.365--1.386                                                      
  AJCC-T                Medicaid            1.251                               1.144--1.370   \<0.001        
  Uninsured             1.566               1.553--1.578                                                      
  AJCC-N                Medicaid            1.040                               0.952--1.137   0.014          
  Uninsured             1.251               1.240--1.263                                                      
  AJCC-M                Medicaid            1.206                               1.066--1.365   \<0.001        
  Uninsured             1.214               0.992--1.486                                                      
  Rectosigmoid/rectum   AJCC stage          Medicaid                            1.392          1.268--1.528   \<0.001
  Uninsured             1.433               1.404--1.463                                                      
  AJCC-T                Medicaid            1.481                               1.337--1.640   \<0.001        
  Uninsured             1.992               1.955--2.030                                                      
  AJCC-N                Medicaid            1.121                               1.014--1.239   0.052          
  Uninsured             1.119               1.095--1.144                                                      
  AJCC-M                Medicaid            1.603                               1.397--1.839   \<0.001        
  Uninsured             1.516               1.220--1.884                                                      

AJCC -- the American Joint Committee on Cancer; OR -- odds ratio; CI -- confidence interval. The multivariate logistic model included age group, gender, year of diagnosis, marriage, race, household income, college completion and residence for adjustment.

###### 

Multivariate logistic regression analysis of association between definitive treatment and insurance status.

  Characteristic            Univariate analysis   Multivariate analysis                                         
  ------------------------- --------------------- ----------------------- --------- ----------- --------------- ---------
  Gender                                                                  \<0.001                               
   Female                   238                   25196                             Reference                   
   Male                     330                   28468                             0.728       0.611--0.867    \<0.001
  Age group (years)                                                       \<0.001                               
   18--54                   95                    12409                             Reference                   
   55--64                   111                   13217                             0.821       0.621--1.084    0.165
   65--74                   134                   14451                             0.587       0.446--0.773    \<0.001
   75--85                   228                   13587                             0.275       0.213--0.357    \<0.001
  Year of diagnosis                                                       0.301                                 
   2007                     176                   18141                                                         
   2008                     191                   17869                                                         
   2009                     201                   17654                                                         
  Marital status                                                          \<0.001                               
   Married                  258                   32519                             Reference                   
   Unmarried                310                   21145                             0.634       0.531--0.757    \<0.001
  Race                                                                    \<0.001                               
   Asian/Pacific Islander   39                    4650                              Reference                   
   Black                    117                   6310                              0.558       0.379--0.823    0.003
   Hispanic white           75                    5345                              0.693       0.465--1.034    0.073
   Non-Hispanic white       337                   37359                             1.086       0.765--1.541    0.645
  Insurance status                                                        \<0.001                               
   Insured                  421                   46353                             Reference                   
   Medicaid                 108                   5543                              0.591       0.470--0.742    \<0.001
   Uninsured                39                    1768                              0.404       0.282--0.579    \<0.001
  Income                                                                  \<0.001                               
   Quartile 1               114                   13759                             Reference                   
   Quartile 2               107                   13286                             0.773       0.559--1.068    0.119
   Quartile 3               151                   13840                             0.667       0.481--0.923    0.015
   Quartile 4               196                   12779                             0.510       0.348--0.749    \<0.001
  Education                                                               \<0.001                               
   Quartile 1               136                   13754                             Reference                   
   Quartile 2               146                   15350                             1.405       1.049--1.883    0.023
   Quartile 3               100                   11383                             1.809       1.280--2.558    \<0.001
   Quartile 4               186                   13177                             1.400       0.978--2.003    0.066
  Residence                                                               \<0.001                               
   Metropolitan             461                   46808                             Reference                   
   Rural                    107                   6856                              0.723       0.557--0.938    0.015
  Cancer site                                                             \<0.001                               
   Left colon               139                   16104                             Reference                   
   Right colon              168                   22501                             1.278       1.016--1.607    0.036
  Rectosigmoid/rectum       261                   15059                             0.442       0.358--0.545    \<0.001
  SEER stage                                                              \<0.001                               
   Distant                  209                   8292                              Reference                   
   Localized                302                   22269                             1.980       1.648--2.379    \<0.001
   Regional                 57                    23103                             10.998      8.180--14.785   \<0.001

OR -- odds ratio; CI -- confidence interval; SEER -- the Surveillance, Epidemiology and End Results.

###### 

The multivariate Cox model and the Fine and Gray proportional sub-distribution hazard model for tumor cause-specific survival in patients with colorectal cancer.

  Characteristics               Multivariate Cox model   Fine and Gray model                                      
  ----------------------------- ------------------------ --------------------- ----------- ------- -------------- ---------
  Gender                                                                                                          
   Female                       Reference                                                                         
   Male                         1.096                    1.060--1.133          \<0.001                            
  Age group (years)                                                                                               
   18--54                       Reference                                      Reference                          
   55--64                       1.126                    1.075--1.180          \<0.001     1.111   1.059--1.164   \<0.001
   65--74                       1.351                    1.288--1.416          \<0.001     1.261   1.200--1.325   \<0.001
   75--85                       1.910                    1.819--2.006          \<0.001     1.634   1.549--1.723   \<0.001
  Marital status                                                                                                  
   Married                      Reference                                      Reference                          
   Unmarried                    1.161                    1.122--1.201          \<0.001     1.110   1.071--1.151   \<0.001
  Race                                                                                                            
   Asian/Pacific Islander       Reference                                      Reference                          
   Black                        1.380                    1.283--1.486          \<0.001     1.385   1.283--1.495   \<0.001
   Hispanic white               1.058                    0.980--1.143          0.147       1.070   0.986--1.160   0.100
   Non-Hispanic white           1.094                    1.028--1.163          0.005       1.109   1.041--1.182   0.002
  Insurance status                                                                                                
   Insured                      Reference                                      Reference                          
   Medicaid                     1.298                    1.236--1.363          \<0.001     1.260   1.192--1.332   \<0.001
   Uninsured                    1.195                    1.100--1.297          \<0.001     1.143   1.041--1.256   0.005
  Income                                                                                                          
   Quartile 1                   Reference                                                                         
   Quartile 2                   1.050                    0.990--1.114          0.102                              
   Quartile 3                   1.039                    0.977--1.104          0.228                              
   Quartile 4                   1.086                    1.010--1.167          0.025                              
  Education                                                                                                       
   Quartile 1                   Reference                                      Reference                          
   Quartile 2                   0.995                    0.941--1.052          0.861       1.012   0.966--1.061   0.610
   Quartile 3                   1.054                    0.988--1.124          0.110       1.072   1.018--1.128   0.008
   Quartile 4                   1.110                    1.035--1.189          0.003       1.139   1.086--1.195   \<0.001
  Cancer site                                                                                                     
  Left colon                    Reference                                      Reference                          
   Right colon                  1.059                    1.017--1.102          0.005       1.027   0.985--1.070   0.210
   Rectosigmoid/rectum          1.137                    1.081--1.197          \<0.001     1.128   1.070--1.189   \<0.001
  Histology                                                                                                       
   Adenocarcinoma               Reference                                      Reference                          
   Mucinous adenocarcinoma      1.084                    1.019--1.152          0.011       1.074   1.006--1.147   0.033
   Signet ring cell carcinoma   1.446                    1.275--1.640          \<0.001     1.269   1.060--1.520   0.010
  Grade                                                                                                           
   I                            Reference                                      Reference                          
   II                           1.192                    1.107--1.284          \<0.001     1.179   1.094--1.270   \<0.001
   III                          1.531                    1.413--1.658          \<0.001     1.491   1.374--1.617   \<0.001
   IV                           1.517                    1.333--1.726          \<0.001     1.481   1.274--1.721   \<0.001
  AJCC stage                                                                                                      
   I                            Reference                                      Reference                          
   II                           1.306                    1.170--1.457          \<0.001     1.290   1.153--1.444   \<0.001
   III                          2.095                    1.832--2.396          \<0.001     2.035   1.767--2.344   \<0.001
   IV                           5.329                    4.497--6.313          \<0.001     4.560   3.813--5.453   \<0.001
  AJCC-T                                                                                                          
   T1                           Reference                                      Reference                          
   T2                           0.837                    0.764--0.917          \<0.001     0.856   0.780--0.940   0.001
   T3                           1.315                    1.210--1.429          \<0.001     1.347   1.230--1.475   \<0.001
   T4                           2.026                    1.858--2.209          \<0.001     1.977   1.792--2.180   \<0.001
  AJCC-N                                                                                                          
   N0                           Reference                                      Reference                          
   N1                           1.148                    1.073--1.228          \<0.001     1.122   1.040--1.211   0.003
   N2                           1.939                    1.814--2.072          \<0.001     1.836   1.701--1.981   \<0.001
  SEER stage                                                                                                      
   Localized                    Reference                                      Reference                          
   Regional                     1.314                    1.212--1.424          \<0.001     1.298   1.198--1.407   \<0.001
   Distant                      2.257                    1.967--2.589          \<0.001     2.325   2.015--2.682   \<0.001
  Surgery                                                                                                         
   Yes                          Reference                                      Reference                          
   No                           2.970                    2.782--3.169          \<0.001     2.530   2.320--2.760   \<0.001
  Radiotherapy                                                                                                    
   Yes                          Reference                                      Reference                          
   No                           0.891                    0.844--0.940          \<0.001     0.897   0.845--0.953   \<0.001
  Chemotherapy                                                                                                    
   Yes                          Reference                                      Reference                          
   No                           1.251                    1.201--1.303          \<0.001     1.120   1.069--1.173   \<0.001

HR -- hazard ratio; CI -- confidence interval; sHR -- sub-distribution hazard ratio; AJCC -- the American Joint Committee on Cancer; SEER -- the Surveillance, Epidemiology and End Results.
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